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ABSTRACT 
Introduction: in vitro drug sensitivity relies on the growth of Plasmodium in the presence of the antimalarials. These fresh 
isolates brought in for assay from collection sites normally not near the laboratory require a medium to keep the parasites 
viable in order to produce results which are a representation of the field situation in terms of drug susceptibility. However, 
factors  such  as  mixed  infection  of  drug resistant and  sensitive  parasites o c c u r r i n g  i n  m o s t  f i e l d  
i s o l a t e s  can  influence  drug  test  outcome because they have different drug susceptibilities, thus there is a need of 
using clones which have identified these drug resistant sub populations to prevent treatment failures, misidentification of 
a populations susceptibility profile and also in any evaluation procedure so as to provide accurate test results. Objective: This 
study validated the use of a formulated transport medium (TM) by assaying clones which have been culture adapted in the lab 
for 50% inhibitory concentrations (IC50) against four antimalarials using SYBR Green 1 in vitro assay. Method: These clones 
(3D7 and W2) were revived and culture adapted for assay. Prior to subjecting them to drugs, they were exposed to 2ml 
formulated TM and the conventional EDTA anticoagulant in 5ml vacutainer tubes to act as control. Results: Both clones 
gave successful assays with moderate RFU values of between 2000 to 4000 parasites obtained by 3D7clone while W2 had 
RFU values as high as 20,000 parasites. However, their curves converged into discernible dose-response curves. 
Similarity was detected with no significant difference (P >0.05) observed in the medians inhibitory concentration 50 (IC50) 
between samples in the EDTA anticoagulant and TM however, samples in EDTA generally had higher IC50 values. 
Conclusion: This study concludes that the formulated TM holds promise for future use. 
Introduction 
In Kenya Malaria is still the leading cause of morbidity and mortality (Kenya Ministry of Public Health and Sanitation, 
2009). The disease accounts for 30 percent of Kenya’s outpatient visits, 19 percent of hospital admissions, two to three 
percent of inpatient deaths, and is a leading cause of death among children under the age of five (Kenya Ministry of Public 
Health and Sanitation 2011). Specifically, in Western Kenya, 32% of all deaths are associated with Malaria, It causes 22% 
deaths among children with severe malaria, out of which 10% occur in hospitals and 13% outside hospitals within 8 weeks 
after admission. Also, treatment of malaria with chloroquine in the region was associated with 33% case fatality rate 
compared to 11% for children treated with more effective regime (Jane et al., 1996). A variety of drugs have been used to 
treat malaria in Kenya over the years, including quinine and related compounds such as chloroquine, antifolate combination 
drugs, antibiotics, and artemisinin compounds. Efforts to control the spread of the disease, however, are hampered by a 
growing trend of resistance to antimalarial medications. This is a great concern to the Kenyan government, whose goal is to 
decrease morbidity and mortality due to malaria by 30 percent by 2017 (Kenya Ministry of Public Health and Sanitation 
2011). It is predicted that clinical infections and death will begin to increase due to rapid spread of drug resistance parasites 
(Hastings and Alessandro, 2000).  
In addition to resistance to antimalarial combination therapies, there is also a concern with Plasmodium mixed 
infections. A mixed infection is defined as an infection with more than one type of species or genotype of Plasmodium 
(Ferdig and Su, 2000). Other groups have noted that a number of malarial infections are heterogeneous in their 
composition (Lorenzetti et al., 2008). Mixed infections of different genotypes are highly prevalent in malaria-endemic 
areas, particularly in Africa and Southeast Asia (Kobbe et al., 2006). In fact, almost all infections occurring in nature 
are mixed. Although highly understudied, the implications of a mixed infection are profound. They can cause a relapse 
as a result of emergence of the resistant subpopulation of parasites after the sensitive subpopulation has been 
eradicated by drug therapy. The existence of a resistant  population may be a result of both divergent  evolution,  where  
parasites  have acquired  resistance mechanisms,  and/or  two cohabitating parasites  when the individual  is infected  
(Hyde, 2002).  This phenomenon has been observed in areas of malaria endemicity in Africa and Southeast Asia where 
the mixed-infection prevalence is as high as 30% (Mayxay et al., 2004). However, there has been conflicting evidence as 
to the true frequency of Plasmodium mixed infections (Richie, 1988). Furthermore, this problem is confounded by the 
inability to properly identify and differentiate Plasmodium mixed infections. This phenomenon is possibly due to the 
assay’s detection limit, where susceptibility of one population ceases to affect the profile of the other subpopulation, 
effectively masking the existence of that subpopulation. At this low parasite subpopulation level, dominance of a 
resistance mechanism may not be high enough in the population and may result in the appearance of only one 
phenotype. The reverse is also possible, where a large susceptible subpopulation may influence the apparent phenotype 
of the whole population. Most naturally occurring malaria infections are composed of mixed subpopulations with 
different drug susceptibilities (Postigo et al., 1998). It is likely that mixed infections of both drug sensitive and resistant 
parasites in a patient will produce test readings not representative of a typical resistant or sensitive parasite. Thus, 
there is a need of using clones which have identified these drug resistant sub populations to prevent treatment failures, 
misidentification of a populations susceptibility profile (Zimmerman et al., 2004) and also in any evaluation procedure so as 
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to provide accurate test results. This study validated the use of a formulated TM by assaying P. falciparum reference clones. 
W2 considered as chloroquine resistant, mefloquine sensitive and artemisinin sensitive and 3D7 considered as chloroquine 
sensitive and mefloquine sensitive clones were used. 
Materials and methods 
Ethical consideration 
This study was approved by Jaramogi Oginga Odinga teaching and referral hospital Ethics and review committee (JOOTRH 
ERC). 
Sample preparation 
These are clones which were kept in liquid nitrogen and needed to be culture adapted for the experiment. First the isolates 
were removed from liquid nitrogen and indicated in the nitrogen freezer log sheet, and then the vials were left to thaw in the 
incubator. Once the content liquefied it was transferred aseptically in to a 15ml centrifuge tube noting the volume. Slowly 
1/5volume of 12% solution Nacl was added while swirling the tube. It was allowed to stand at room temperature for 5 
minutes. 9 volume of 1.6%Nacl solution was added to it and was centrifuged at 1500rpm for 3minutes. Supernatant was 
aspirated before another 9volume of 0.9%Nacl and 0.2% dextrose solution were added. This was mixed gently and 
centrifuged at 1500rpm for 3min, and then supernatant was aspirated. It was resuspended in culture medium by adding 4.5ml 
of 10% complete medium and 0.5ml of washed Rbcs for a 5ml culture. Then the culture was gassed and placed in an 
incubator at 370c to grow. Medium was being changed after every 48 hours while gassing the bottles.  Parasitaemia was 
checked three times weekly until the parasitaemia was 3-8%.  
Once the clones were ready for assay they were subjected to EDTA and the formulated TM for at least 6hours before they 
were washed in RPMI 1640 by centrifugation at 2500 revolutions per minute for 3minutes for three consecutive times. 
samples with > 1% parasitemia were adjusted to1% parasitemia at 2% hematocrit using uninfected O+ 
erythrocytes, and those with ≤ 1% parasitemia were used unadjusted at 2% hematocrit. Transfer of parasite sample 
and antimalarial drug aliquots in complete RPMI 1640 drug aliquots onto 96-well microculture plates and addition of 
lysis buffer after 72 hours incubation was done as previously described (Johnson et al., 2007).The plates were then 
placed at room temperature in the dark, for 5–15 minutes.  Parasite replication inhibition was quantified and the 
IC50   for each drug calculated by an equation generating a sigmoidal concentration response curve (variable slope),  
with  log  transformed drug  concentrations on  the  X axis and  relative  fluorescent units  (RFUs) on  the Y axis 
(Graphpad Prism for Windows, version  5.0; Graphpad Software, Inc., San Diego, CA). (Bacon et al., 2007). 
Results 
Reference Plasmodium falciparum clones were assayed against a panel of antimalarials namely atermether, lumefantrine, 
Dihydroartemisinin and piperaquine.W2 considered as chloroquine resistant, mefloquine sensitive and artemisinin sensitive  
and 3D7 considered as chloroquine sensitive and mefloquine sensitive were used. Both clones were revived from liquid 
nitrogen and cultured for in vitro adaptation.  Prior to exposing them to the respective drugs, they were subjected to EDTA 
and the formulated TM in a 5ml vacutainer tubes for the same duration as the field isolates and washed using complete 
medium. Both clones gave successful assays in 95% of the plates in both EDTA and TM. Moderate RFU values of between 
2000 to 4000 parasites were obtained by 3D7clone while W2 had RFU values as high as 20,000 parasites. However, as shown 
in figure 1 below, their curves converged into a discernible dose-response curve for IC50 determinations with most/all 
of the points of the 10 standard dilutions included in the sigmoidal curve, for 90% of the plates and recording a reliability 
value (r2) of almost 1 (to be specific 0.9999).  
For W2 clone the IC50 values in ng/ml for the samples in EDTA were all higher than their respective IC50 values in TM as 
shown in table 1 below .The same table continues to show that there was no significant difference in IC50 values in samples 
treated with LUM (32.61 vs 29.32 ng/ml, p=0.369) and DHA (18.22 vs 14.93 ng/ml, P=0.2084). However, a high significant 
decrease in IC50 values for samples in TM was recorded when they were subjected to ART (3.118 vs1.873 ng/ml, p<0.001) 
and PPQ (18.93 vs 11.41 ng/ml, p=<0.001). ART emerged to have the best activity with the least IC50 values for samples in 
both EDTA and TM thus coinciding with the fact that W2 is artemisinin sensitive. On the other hand, LUM which is the first 
line partner drug to ART in treatment of uncomplicated malarial had the highest IC50 values in EDTA (32.61ng/ml) and TM 
(29.32ng/ml). As seen in figure 2 below, samples in both categories had the lowest individual IC50 of 20 and 21 ng/ml. 
Compared to W2, 3D7 clone generally showed reduced IC50 values for all the antimalarials for samples in EDTA and TM. 
Unlike W2, samples in EDTA had lower IC50 values than samples in TM as shown in table 2. However, there was no 
significant difference for samples exposed to ART (1.667 vs 2.353 ng/ml, p= 0.255) and LUM (22.27 vs 9.905 ng/ml, 
p=0.3377) in the two categories, while there was a high significant decrease for samples in TM when they were treated with 
DHA (2.853 vs 10.03 ng/ml, p= 0.009) and PPQ (1.181 vs 13 ng/ml, p=0.028). Notably, in both clones, PPQ is the only drug 
with a persistent significant difference in IC50 values in the two anticoagulants. PPQ and ART had close IC50 ranges between 
the minimum and the maximum values as shown in the figures 3 below. 
Using pearsons correlation coefficient, there was no correlation significance (P>0.05) between the two anticoagulants as 
indicated by their r values shown in table 3 and 4 below. However, no significant difference (P>0.05) was observed between 
the individual activities of drugs as illustrated earlier in tables 1 and 2. 
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Discussion 
Among the assays of the reference clones, in both anticoagulants, the IC50 range between the individual minimum and 
maximum values were small, this reflects reduced biological variability due to the absence of resistant and sensitive 
subpopulations of parasites, therefore, they were able to produce distinct IC50 dose response curves with most points of the 
standard dilutions include in the sigmoidal curve. This is in accordance with a study which argued that a pure parasite 
population either  resistant  or  sensitive  to  a drug,  will produce a curve with a sharp  inhibition of parasite growth  at 
a relatively  narrow range of drug concentration, whereas  a mixed population with a minor  resistant  population of 
10% or higher  will produce a flattened curve or a double-hump curve, reflecting  two parasite populations with 
different IC50.(Liu et al., 2008). Nonetheless, it has been reported that among the field isolates, most naturally occurring 
malaria infections are composed of mixed subpopulations with different  drug  susceptibilities (Postigo et al.,1998, 
Zimmerman et al., 2004) but a large susceptible or resistant subpopulation  may  influence  the  apparent phenotype   of  
the  whole population (Co-em et al., 2009), a factor relevant to the current finding. On the other hand, W2 considered 
chloroquine resistant demonstrated an aspect of ‘resistance’ in all the drugs by having elevated IC50 values in all the drugs 
except for ART since its considered artemisinin sensitive.  
The high significant decrease in the medians for the W2 samples exposed to ART and PPQ and also a slight significant 
difference for DHA and PPQ in the 3D7 samples would have been affected by the selection of subpopulations in a clinical 
sample during initial culturing and isolation of the clones, since it has been reported that when clinical strains  are  culture  
adapted, they result in possible  loss of the minor  subpopulation and  consequent misidentification of the 
population’s  susceptibility  profile (Basco and Lebras, 1994, Basco and Lebras, 1990). Also in line with a finding which was 
concerned that during culture adaptation there could be selection of a dorminant clone (Liu et al., 2008). Anyway, other 
studies have also shown that even with culture adaptation, the minor subpopulation is still detectable (Mbaisi et al., 
2004).  
Additionally, the PPQ activities of 3D7 and W2 in both anticoagulants obtained in the current study were in line 
with the PPQ activities of 8.3 and 16 ng/ml in chloroquine sensitive and chloroquine resistant clones obtained by 
Vennerstrom et al., (1992). It was further observed that PPQ and LUM among the clones had the least activity, and 
this could have been attributed by the fact that the drugs are longer acting partner drugs to artemis inin derivatives 
with much longer half life, of 3-4 days and 3-4 weeks for LUM and PPQ respectively (German and Aweeka, 2008) 
thus, in subsequent infections they are exposed to sub-therapeutic concentrations of these drugs, facilitating 
selection of parasites. 
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Figure 1: Example of sigmoidal curves generated by clones indicating RFU values against the concentration of a drug. 
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Figure 2: In vitro distribution of W2 IC50 values for samples in EDTA and TM 
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Table 1: Drug susceptibility testing of W2 reference clone in EDTA and TM against a panel of antimalarials 
 Median IC50 in ng/ml for W2 P. falciparum reference clone 
transported in: 
 
 EDTA TM 
DRUGS n median IQR  median IQR p-
value 
Artemether (ART) 26 3.118 1.985-
6.455 
1.873 1.514-4.403 <0.001 
Lumefatrine (LUM) 24 32.61 20 - 40.9 29.32 20.56-47.6 0.3697 
Diydroartemisinin 
(DHA) 
20 
 
18.22 0.106-
37.92 
14.93 1.283-124.2 0.2084 
Piperaquine (PPQ) 26 18.93 10.92-
22.06 
11.41 4.68-26.11 <0.001 
Comparison of the medians using Mann - whitney test 
Key: TM= Transport medium, n= number of samples, IQR=interquartile range, p = significance level of the test 
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Figure 3: In vitro distribution of 3D7 IC50 values for samples in EDTA and TM 
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Table 2: 
Drug susceptibility testing of 3D7 reference clone in EDTA and TM against a panel of antimalarials 
 Median IC50 in ng/ml for 3D7 P. falciparum reference clone 
transported in: 
 
 EDTA TM 
DRUGS n median IQR  median IQR p-
value 
Artemether (ART) 22 1.667 0.131- 
9.09 
2.353 0.1824-28.2 0.2549 
Lumefatrine (LUM) 24 22.27 0.417 - 
48.1 
9.905 1.078-41.62 0.3377 
Diydroartemisinin 
(DHA) 
20 
 
2.853 0.441-
19.3 
10.03 0.166-77.09 0.0098 
Piperaquine (PPQ) 23 7.181 1.88 - 
20.45 
13 0.374 - 92 0.028 
Comparison of the medians using Mann - whitney test 
Key: TM= Transport medium, n= number of samples, IQR=interquartile range, p = significance level of the test 
Table 3: Correlations between EDTA and TM: results for W2 reference clone 
Sample in EDTA vs TM 
subjected to: 
Correlation coefficient (r Probability 
P value 
ART-ART -0.0110 0.9611 
LUM-LUM -0.277 0.1901 
DHA-DHA -0.2577 0.2727 
PPQ-PPQ -0.1487 0.4983 
 
Table 4: Correlations between EDTA and TM: results for 3D7 reference clone 
Sample in EDTA subjected 
to: 
Correlation coefficient (r) Probability 
P value 
ART-ART 0.03275 0.8765 
LUM-LUM 0.156 0.4771 
DHA-DHA -0.021 0.9297 
PPQ-PPQ -0.3025 0.1416 
Correlation of the activity of antimalarials using Pearson’s correlation coefficient of log IC50 values.  
Key; P= significance level of the test, ART= Artemether, LUM= Lumefantrine, DHA= Dihydroartemisinin and 
PPQ= Piperaquine 
